Sickle Cell · Idaho
Sickle cell disease resources in Idaho
Idaho's small SCD population is served by St. Luke's Children's and by referral to Seattle Children's and OHSU. There is no SCDAA chapter in Idaho; community support is routed through the national SCDAA Connect line.
Idaho began universal newborn screening for sickle cell disease in 1992 — every baby born in the state is now screened at birth, which lets families start twice-daily penicillin prophylaxis by two months old and dramatically reduces childhood SCD mortality. For confirmatory testing and hematology follow-up after a positive screen, ask your pediatrician for a referral to the closest comprehensive sickle cell center listed on this page.
Idaho Medicaid covers hydroxyurea — the cornerstone disease-modifying therapy for SCD. Idaho Medicaid covers Casgevy and Lyfgenia on a case-by-case prior-authorization basis. As of 2026, only roughly 45 comprehensive centers nationally are authorized to administer Casgevy (exa-cel), and fewer still are authorized for Lyfgenia (lovo-cel). Coverage status alone doesn't guarantee access — patients must be at least 12 years old with recurrent vaso-occlusive crises, enrolled at an authorized center, and cleared through the center's multi-step stem-cell-collection and conditioning protocol.
Idaho does not have a standalone SCDAA chapter. For community support, the national SCDAA Connect line at 1-800-421-8453 routes callers to the nearest chapter and to local hospital social-work teams experienced with SCD care coordination.
Idaho at a glance
- Newborn screening start
- 1992
- Estimated SCD patients in state
- Not published
- Medicaid: hydroxyurea
- Covered
- Medicaid: CRISPR gene therapy
- Case-by-case prior authorization
For Black families
Roughly 1 in every 365 Black infants born in the United States inherits sickle cell disease, and roughly 1 in 13 carries the sickle cell trait — the highest carrier frequency of any population group in the country. Because newborn screening is universal, nearly every Black family in Idaho whose baby has SCD receives the diagnosis before they leave the hospital — which is exactly why timely follow-up with a comprehensive center matters more than the diagnosis itself.
The hardest periods in the SCD lifespan are the transition from pediatric to adult care (roughly ages 18-25, when preventable mortality peaks) and emergency-department visits for vaso-occlusive crises, where published research has consistently documented longer time-to-analgesia and higher suspicion of drug-seeking behavior for Black SCD patients than for white patients with comparable pain. Transition programs, pain plans, and hematologist letters addressed to ED staff reduce both. Every comprehensive center listed on this page supplies those materials on request.
Where to get help in Idaho
- Hematology-oncology providers in Idaho: /providers/?state=ID&specialty=hematology-oncology. Filter our directory to hematology-oncology specialists.
- Federally Qualified Health Centers in Idaho: /clinics/id/. FQHCs accept Medicaid, charge on a sliding scale, and are the practical first stop when you need a primary-care home that will coordinate SCD specialty referrals.
- Idaho Medicaid: /medicaid/idaho/ covers eligibility, how to apply, and our idaho tracker for 12-month postpartum extension + doula coverage — relevant to pregnant people carrying sickle cell trait or SCD.
- CDC Sickle Cell Data Collection program: cdc.gov/ncbddd/hemoglobinopathies/scdc publishes claims-based SCD prevalence for participating states.
- National SCDAA Connect line: 1-800-421-8453. Routes callers to local chapter resources and hospital social-work teams experienced with SCD.
References
- NHLBI, "Evidence-Based Management of Sickle Cell Disease" (2014 expert panel report): nhlbi.nih.gov.
- American Society of Hematology 2020 SCD Clinical Practice Guidelines: hematology.org.
- CDC Sickle Cell Data Collection program: cdc.gov/ncbddd/hemoglobinopathies/scdc.
- Baby's First Test, state-by-state newborn screening panel: babysfirsttest.org.
- FDA approvals, December 2023: Casgevy (exagamglogene autotemcel, Vertex) + Lyfgenia (lovotibeglogene autotemcel, bluebird bio), CRISPR-based gene therapies for severe SCD.
Data refreshed: